Tags: MRSA | drug | antibiotic | Dalvance | infections

New MRSA Treatment

Tuesday, 27 May 2014 12:21 PM

 
The intravenous antibiotic Dalvance (dalbavancin) has been approved by the U.S. Food and Drug Administration to treat methicillin-resistant Staphylococcus aureus (MRSA) and other potentially deadly bacterial skin infections that have become resistant to older antibiotics.
Dalvance was given priority review and designated a "Qualified Infectious Disease Product" (QIDP) since it is meant to treat serious bacterial or fungal infections, the FDA said in a news release.
The drug's safety and effectiveness were evaluated in clinical studies involving 1,289 people with acute bacterial skin infections. The most common side effects noted were nausea, headache and diarrhea. Study participants who took Dalvance also showed a higher-than-expected incidence of elevated liver enzymes in one screening test, the agency said.

© HealthDay

 
1Like our page
2Share
FDA-Approved-Drugs
The intravenous antibiotic Dalvance (dalbavancin) has been approved by the U.S. Food and Drug Administration to treat methicillin-resistant Staphylococcus aureus (MRSA) and other potentially deadly bacterial skin infections that have become resistant to older...
MRSA, drug, antibiotic, Dalvance, infections
116
2014-21-27
Tuesday, 27 May 2014 12:21 PM
Newsmax Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved